erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.
.official guidelines say no one should wait more than 62 days to get cancer care after an urgent referral by their gp
.
.
.